EYU688 / Novartis - LARVOL DELTA

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jan 2027 ➔ Jul 2027 | Trial primary completion date: Jan 2027 ➔ Jul 2027

Trial completion date • Trial primary completion date • Dengue Fever

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2026 ➔ Jan 2027 | Trial primary completion date: Sep 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Dengue Fever

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2026 ➔ Sep 2026 | Trial primary completion date: Feb 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Dengue Fever

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Recruiting

Enrollment open • Dengue Fever

Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition. (PubMed, Molecules) - "NS3-NS4B inhibitors, such as JNJ-64281802 and EYU688, show promise, recently entering clinical trials, underscoring the importance of developing novel viral replication inhibitors targeting viral machinery. To date, the only NS2B-NS3 inhibitor that has undergone clinical trials is doxycycline, however, its mechanism of action and clinical efficacy as viral growth inhibitor require additional investigation. SYC-1307, an allosteric inhibitor, exhibits high in vivo efficacy, while temoporfin and methylene blue represent promising orthosteric non-competitive inhibitors. Compound 71, a competitive NS2B-NS3 inhibitor, emerges as a leading preclinical candidate due to its high cellular antiviral efficacy, minimal cytotoxicity, and favorable in vitro pharmacokinetic parameters. Challenges remain in developing competitive NS2B-NS3 inhibitors, including appropriate biochemical inhibition assays as well as the selectivity and conformational flexibility of the protease, complicating..."

Journal • Preclinical • Review • Dengue Fever • Infectious Disease

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Oct 2025 ➔ Feb 2026 | Trial primary completion date: Sep 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Dengue Fever

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=108 ➔ 5 | Trial completion date: Jun 2025 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Sep 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Dengue Fever

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Jan 2025 ➔ May 2025

Trial completion date • Trial primary completion date • Dengue Fever

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Dengue Fever

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (clinicaltrials.gov) - P2 | N=108 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Dengue Fever